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Background: Contamination of therapeutic recombinant proteins with residual host cell DNA must be controlled under the regulatory standards.
Objectives: The current study established a new rapid, sensitive real time polymerase chain reaction (PCR) approach to measure the reliably of the residual Escherichia coli (E. coli) host cell genomic DNA in the recombinant streptokinase and alfa interferon preparations.
Materials and Methods: In this assay, a specific primer pair was utilized to amplify a 115 base pair sequence inside the E. coli 16S rRNA using SYBR Green Chemistry. This method enabled the authors to detect a very small quantity of the residual genomic DNA, as low as 0.8 pg, in the protein-based drugs. This method can, therefore, offer a dependable way to quantitatively analyze the major contaminant of biopharmaceutical products, the host cell DNA, during the manufacturing process.
Results: SYBR Green PCR master mix may contain a source of DNA contamination during its manufacturing process.
Conclusions: The current study data showed that E. coli host cell DNA contamination in streptokinase and alfa interferon manufactured in the Pasteur institute of Iran is much lower than the safety limits suggested by the FDA.
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1. BackgroundRecombinant therapeutic proteins are extensively used as biopharmaceutical products for human thera-pies. They can be expressed in bacteria, yeasts, mam-malian cells, or in transgenic plants and animals (1, 2). Escherichia coli is one of the most commonly used host cells to produce biopharmaceuticals due to its well-characterized genetic map, and rapid growth on inex-pensive substrates (3-5). Despite the fact that employ-ment of E. coli as an expression system has substantial advantages to manufacture therapeutic proteins, con-tamination of the bioproducts with the bacterial DNA is a major concern during the manufacturing process. Residual E. coli genomic DNA in biopharmaceuticals is considered as a potential risk factor (6). It is suggested that the DNA-based contaminants could act as antigens or immunogenic agents in the patients receiving the protein- based drugs. It is also hypothesized that the DNA impurities could be integrated into the genome of the recipient cells and express a new foreign gene, or alter the level of gene expression (7). It is, therefore, cru-
cial for the pharmaceutical industries to quantitatively monitor the DNA impurities (8) and keep the amount of the DNA contaminants in the bioproduct preparations as low as the safety limit suggested by the regulatory au-thorities such the food and drug administration (FDA) (9). Recently, real time polymerase chain reaction (PCR) assay is greatly aimed as a new method to detect and quantify PCR products simultaneously (10). Real time PCR is already employed to detect bacterial, fungal and viral loads in recombinant therapeutics (11-15). The cur-rent study established a new highly sensitive real time PCR approach based on SYBR Green Chemistry to detect a very small quantity of the residual E. coli host cell DNA in the recombinant streptokinase and alfa interferon samples produced in the Pasteur Institute of Iran. Strep-tokinase and interferon are recombinant protein-based drugs produced in E. coli host cells (16, 17). Streptokinase is clinically used as an intravenous thrombolytic agent to treat acute myocardial infarction (18). Interferons are a family of cytokines, acting as integral parts of the in-
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nate immune response. As secreted ligands, interferons target specific cell surface receptors (19), eliciting the interferon-mediated antiviral response through four main pathways (20). Collectively, the obtained data showed that the innovative real time PCR method ex-ploited, offers a precise reliable way to detect the E. coli DNA contaminants as low as 0.8 pg in the bioproduct preparations.
2. ObjectivesThe current study established a new rapid, sensitive real time Polymerase Chain Reaction (PCR) approach to mea-sure the reliably of the residual Escherichia coli (E. coli) host cell genomic DNA in the recombinant streptokinase and alfa interferon preparations.
3. Materials and Methods
3.1. Experimental
3.1.1. Cell CultureEscherichia coli W3110 strain was provided by the Pasteur Institute, Iran. A single colony of this strain was inocu-lated into 5 mL of Luria-Bertani (LB) broth, and incubated overnight at 37˚C , shaking at 250 rpm.
3.1.2. Preparation of Escherichia coli Genomic DNAThe cells were recovered by centrifugation at 12 rpm for two minutes. Genomic DNA was purified using DNeasy Blood & Tissue kit (Qiagen Co., Iran) according to the man-ufacturer’s protocol. DNA concentration was measured by ND-1000 spectrophotometric analysis at 260/280 nm (Biorad Co., USA).
3.1.3. Primer Design and PCR TestFour sets of oligonucleotide forward and reverse prim-ers targeting the conserved region of the eubacterial 16S rRNA gene were designed using Primer Express software of the Applied Biosystems (Foster city Co., USA), and the sequence information was found in the NCBI GeneBank database (Accession Number: J01859). The primers were synthesized by Bioneer Corporation (Korea). PCR reac-tions were carried out in a master cycler personal (Ep-pendorf Co., Germany) using Ex Taq polymerase (TaKaRa Co., Japan) according to the manufacturer’s instruction. The cycle parameters were as follows: initial heat dena-turation at 94˚C for one minute, followed by 35 cycles of denaturation at 94˚C for 20 seconds, annealing at 60˚C for 30 seconds, and extension at 72˚C for 30 seconds. To ensure complete extension, the reaction mixture was incubated for five minutes at 72˚C. The amplified DNA products were analyzed by gel electrophoresis on a 1.5% agarose gel (Sigma Corp Co., USA).
3.1.4. Master Mix PreparationReaction mixture containing nuclease free water and SYBR Premix Ex Taq II (TaKaRa Co., Japan) was incubated with 0.1 U/rxn DNase I (Amersham Co., USA) and 0.5 mM MgCl2, for 60 minutes at 37˚C. In order to inactivate DN-ase I, reaction mixture was heated at 65˚C for 10 minutes.
3.1.5. Optimization of the Real Time PCRTo determine the efficiency of the primers, E. coli genom-ic DNA was serially diluted five-fold. PCR was performed for each set of primer pairs using the serially diluted ge-nomic DNA templates in a Perkin-Elmer 7300 sequence detection system (Applied Biosystem Co., USA). Optimum 
reaction conditions in a total volume of 20 μL were ob-
tained with 10 pM forward primer (0.5 μL), 10pM reverse 
primer (0.5 μL), 2x SYBR Green PCR Master mix (TaKaRa Co., Japan) containing Taq DNA polymerase, SYBR Green I, Tris-HCl, MgCl2, KCl, and deoxynucleotide triphosphate 
(total volume of 10 μL), 0.4 μL ROX (6-carboxy-x-rhoda-
mine), nuclease free water (7.6 μL), and 1 μL template ge-nomic DNA. Amplification was performed with an initial heat denaturation at 95˚C for one minute, followed by 40 cycles of denaturation at 95˚C for 20 seconds, and com-bined annealing/extension at 60˚C for 35 seconds in the 96-well optical plates (Applied Biosystems Co., USA). A mixture of nuclease free water and PCR master mix was used as non template control (NTC) in each experiment. All reactions were run in duplicate.
3.1.6. DNA Extraction From Recombinant Therapeutic ProteinsDue to the presence of inhibitory agents in the final products, DNA was extracted from Active Pharmaceutical Ingredients (API) of streptokinase and alfa interferon. To achieve this purpose, five batches of each drug, produced in five successive weeks, were selected for DNA purifica-tion. After Phenol/Chloroform extraction, supernatant was transferred to a microcentrifuge tube, and DNA was precipitated using 400 mL/L isopropanol. After washing twice with 700 mL ethanol, DNA pellets were resuspend-ed in nuclease free water.
3.1.7. Detection of DNA ContaminationPCR was carried out using seven serially diluted E. coli genomic DNA templates, along with the DNA extracted from each streptokinase and alfa interferon. One microli-ter of each serially diluted E. coli genomic DNA, 1μL of the 
DNA extracted from streptokinase, and 1 μL of the DNA extracted from alfa interferon, in each reaction, were am-plified separately in a total volume of 20 mixture contain-
ing 10 pM forward primer (0.5 μL), 10 pM reverse primer 
(0.5 μL), 2x SYBR Green PCR Master mix (10 μL), 0.4 μL ROX, 
and nuclease free water (7.6 μL). All reactions were run in duplicate. Non template controls were added in the ex-periment. Cycling conditions were one cycle at 95˚C for 
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one minute, followed by 40 cycles at 95˚C for 20 seconds, and 60˚C for 35 seconds.
4. Results
4.1. DNase I TreatmentSYBR Green PCR master mix may contain a source of DNA contamination during its manufacturing process. In order to find the best duration of DNase treatment to eliminate the initial contaminants, 0.1 U/rxn of the DN-ase I was incubated with 10 ng genomic DNA samples in 15, 30, 60, and 120 minutes, separately. In addition, 10 ng of the untreated genomic DNA was used as the negative control. Gel electrophoresis data showed that, in contrast to the negative control, all DNA samples were completely digested upon incubation with the enzyme during all dif-ferent periods (Figure 1). To ensure the complete diges-tion, master mix was treated with DNase I (0.1 U/rnx) for 60 minutes, prior to each PCR performance.
Figure 1. Agarose Gel Electrophoresis of the PCR Products
Lane 1, undigested sample; lane 2, digestion after 15 minutes; lane 3, diges-tion after 30 minutes; lane 4, digestion after 60 minutes; lane 5, digestion after 120 minutes; M, 100 bp ladder.
Table 1.  Sequences of the Oligonucleotide Primer Pairs
Forward Primer Reverse Primer Nucleotide Position PCR Product Size
16S-F1 AGAAGCTTGCTCTTTGCTGA 16S-R1 CTTTGGTCTTGCGACGTTAT 78-197 120
16S-F2 AAAGGAGACTGCCAGTGATA 16S-R2 AGGTCGCTTCTCTTTGTATG 1149-1263 115
16S-F3 CATTGACGTTACCCGCAGAA 16S-R3 CGCTTTACGCCCAGTAATTCC 476-576 101
16S-F4 CCATGAAGTCGGAATCGCTAG 16S-R4 ACTCCCATGGTGTGACGG 1326-1419 94
Figure 2. Optimization of the Real Time PCR Approach to Measure Residual Host Cell DNA
A, amplification curve; B, melting curve analysis; C, standard curve.
Naserpour Farivar T et al.
Biotech Health Sci. 2014;1(3):e263754
4.2. Primer SelectionThe oligonucleotide primers specific for the conserved region of the E. coli 16S rRNA gene were designed (Table 1.). Although, all primer pairs were amplified with the specific target regions, the primer pair 16S2 displayed a greater specificity and efficiency with minimal primer pair formation (data not shown).
4.3. Optimization and Sensitivity of Real Time PCROptimization of the real time PCR depends on several parameters such as primer and cation concentrations, annealing/extension temperature and time, and the length and sequence of template in the reaction mixture. In the current study, the optimal primer and Magnesium concentrations were 10 pM and 4 mM, respectively. The optimal annealing/extension temperature was 60˚C, and the annealing time was 35 seconds. With short amplified sequences (Amplicons), it may be sufficient to touch 95˚C and immediately start cooling (10). The sequence length selected in the current experiment was 115 bp. Seven seri-ally 5-fold dilutions of E. coli genomic DNA from 10,000 pg to 0.8 pg were amplified, and the amplification curve was plotted (Figure 2 A). The sensitivity of this method was 0.8 pg. Melting curve analysis of the PCR products displayed the specific identification of the amplicons without any primer dimer formation (Figure 2 B). In order to quantify 
the products, standard curve was generated by plotting the logarithm of genomic DNA concentration versus cy-cle threshold (Ct) values (Figure 2 C). Agarose gel electro-phoresis of the amplified products showed a 115 bp am-plicon (Figure 3). The standard curve presented Ct values between 15.62 ± 0.028 and 30.06 ± 0.126. Ct values were used to calculate PCR efficiency from the given slope in 
SDS 1.2.3 software according to the equation: Y = -3.58X + 29.65 (R2 = 0.996). PCR efficiency = (10[-1/siope]-1) 100. The PCR efficiency was 94%.
Figure 3. Agarose Gel Electrophoresis of the Amplified Products
Lane 1, 10’000 pg; lane 2, 2000 pg; lane 3‘400 pg; lane 4, 80 pg; lane 5, 16 pg; lane 6, 3.2 pg; lane 7, 0.8 pg; lane 8, negative control.
Figure 4. Accuracy of the Real Time PCR Approach to Measure DNA Contamination in Biopharmaceuticals
A, amplification curve; B, melting curve analysis; C, standard curve.
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Table 2.  DNA Content of Recombinant Protein-Based Drugs
Recombinant Protein Drug Concentration, mg/mL DNA Content, pg/mL of Product
Streptokinase 1.2 0.005
Alfa interferon 1.1 0.015
4.4. Amplification of the DNA Extracted from Strep-tokinase and InterferonSerially diluted E. coli genomic DNA preparations, one pair of negative controls, and the DNA extracted from streptokinase and alfa interferon preparations were run in duplicate (Figure 4 A). Melting curve analysis of the PCR products did not show any primer pair formation (Figure 4 B). The standard curve presented Ct values be-tween 16.23 ± 0.000 and 30.22 ± 0.101 (Figure 4 C). PCR ef-ficiency was calculated from the given slope in SDS 1.2.3 
software according to the equation: Y = -3.31X + 29.16 (R2 = 0.99). The PCR efficiency was 100%.
4.5. Quantitative Detection of Residual Host Cell DNAThe mean of the two Ct values (mCt) obtained from the duplicate amplification of DNA extracted from each streptokinase and alfa interferon, were calculated sepa-rately. The mCt values (36.89 and 35.14 from strepokinase and alfa interferon, respectively), were put instead of Y 
values in the standard curve equation (Y = -3.31X + 29.16), 
to achieve X values. After getting the common logarithm 
of X values, the estimated amount of residual E. coli host cell DNA was achieved from the recombinant therapeu-tic proteins (Table 2). The values calculated from the ex-periments, were much lower than those of the permit-ted by the FDA (9).
5. DiscussionRecombinant therapeutic proteins are extensively used for the human treatment purposes. Host cell genomic DNA contamination in biopharmaceuticals is a great concern. Hence, the FDA and other regulatory agencies have provided specific quality control and safety criteria, which require the manufacturers to quantify DNA impu-rities in all recombinant products at intermediate stages in the process, as well as on the final products (21, 22). The method involved to measure contaminations must be ac-curate and sensitive enough to determine the minimum level of impurities. For years, expensive radioactive-based methods, including the species-specific DNA hybridiza-tion assay were used to quantify the amount of residual host cell DNA in biopharmaceuticals (23). Ji et al. report-ed a safer nonradioactive slot-blot hybridization assay to quantify residual E. coli DNA levels in purified protein drugs with the sensitivity to detect 2.5 pg E. coli DNA (24). Subsequently, Gregory et al. described a safer and less ex-
pensive alternative approach, i.e. PCR amplification and dioxygenin labeling of the genes encoding 5S rRNA fol-lowed by an affinity-based collection to detect 1pg per ml of the extracted E. coli genomic DNA (25). Although the Gregory's detection method seemed very safe and sensi-tive, it was very labor-intensive to be applied routinely in the biopharmaceutical companies. This made investi-gators to search for a more inexpensive and feasible ap-proach that could be applied readily in the companies. Real time PCR is recently reported as an alternative to detect and quantify DNA sequence in a manufacturing product simultaneously. This method, however, was not employed routinely in the pharmaceutical industries mainly because the real time PCR reactions were inhib-ited by various inhibitors present in the biopharmaceuti-cal products (26). The current study established a novel and rapid detection approach for a precise quantitative measurement of residual E. coli host cell DNA in the two widely used recombinant protein-based drugs, i e, strep-tokinase and alfa interferon. This method, which was based on real time PCR technique and SYBR Green Chem-istry, enabled the authors to reliably detect very small quantities of the genomic DNA, as low as 0.8 pg, in one milliliter of the recombinant protein preparations (Fig-ure 2 D). The high sensitivity and specificity of this ap-proach are most probably due to the fact that 16S rRNA gene is present in multiple copies in the genome of all known bacteria, belonging to the eubacterial kingdom (27). Although probes, including those labeled with fluo-rescent dyes or scorpion ones could have been applied to significantly enhance the sensitivity of real time PCR (28, 29), the SYBR Green technology was exploited to establish a reasonably sensitive inexpensive detection approach. It is known that primer dimer formation is one of the major problems with the SYBR Green use. To avoid this problem, the real time PCR reaction condition was opti-mized by designing accurate primers, finding optimal cation (4 mM) and primer concentration (10 pM), and op-timal annealing temperature and time (60˚C for 35 sec-onds). It is also noteworthy that when the real time PCR reactions were initially utilized to quantify the DNA con-taminants, the reactions were restricted by inhibitor(s). To eliminate the inhibitors, the residual host E. coli DNA was first extracted from the Active Pharmaceutical Ingre-dients (API) of biopharmaceuticals and then subjected to the PCR reactions. Moreover, to preclude any DNA cross-contamination, i.e. to remove any possible DNA contami-nants other than the host genomic E. coli DNA, the mas-ter mixtures used for the real time PCR reactions were 
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treated with DNase I prior to the reactions. In summary, the current study succeeded to establish a new real time PCR approach based on SYBR Green Chemistry to amplify highly conserved sequences of the E. coli 16S rRNA gene with a detection accuracy of 0.8pg genomic DNA per ml of the recombinant protein-based drugs. The sensitivity of the current detection method is three times more than that of offered by the slot blot hybridization assay (24). The current study data showed that E. coli host cell DNA contamination in streptokinase and alfa interferon man-ufactured in the Pasteur institute of Iran is much lower than the safety limits suggested by the FDA.
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